March 2021; 8 (2) ArticleOpen Access
Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
Regina Berkovich, Aida Yakupova, Jonathan Eskenazi, Noel G. Carlson, Lawrence Steinman
First published February 15, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000961
Regina Berkovich
From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
MD, PhDAida Yakupova
From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
MD, PhDJonathan Eskenazi
From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
MDNoel G. Carlson
From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
PhDLawrence Steinman
From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
MDImprovement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
Regina Berkovich, Aida Yakupova, Jonathan Eskenazi, Noel G. Carlson, Lawrence Steinman
Neurol Neuroimmunol Neuroinflamm Mar 2021, 8 (2) e961; DOI: 10.1212/NXI.0000000000000961
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarateAmandine Mathias, Sylvain Perriot, Mathieu Canales et al.Neurology: Neuroimmunology & Neuroinflammation, October 11, 2017 -
Research
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M. Hersh, Haleigh Harris, Devon Conway et al.Neurology: Clinical Practice, February 12, 2020 -
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Review
Lymphopenia and DMTs for relapsing forms of MSConsiderations for the treating neurologistEdward J. Fox, Guy J. Buckle, Barry Singer et al.Neurology: Clinical Practice, January 08, 2019